Validation of a claims-based diagnostic code for Stevens-Johnson syndrome in a commercially insured population

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 7, 2012, Pages 760-764

  Eisenberg, Debra F ^a   Daniel, Gregory W ^a   Jones, Judith K ^b   Goehring Jr , Earl L ^b   Wahl, Peter M ^a   Winters, Peter ^c   Levin, Jay ^c   Bohn, Rhonda L ^a  

^a HEALTHCORE INC   (United States)

^b The Degge Group Ltd   (United States)

^c NONE

Author keywords

Adjudication; Administrative claims data; Medical record review; Pharmacoepidemiology; Stevens Johnson syndrome; Validation

Indexed keywords

ARTICLE; HEALTH INSURANCE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MEDICAL RECORD; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; VALIDATION STUDY;

EID: 84863556280     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3276     Document Type: Article

References (16)

1. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
2. Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010; 85: 131-138.
3. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
4. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol 2009; 15: 4449-4452.
5. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med 2008; 40: 129-138.
6. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360.
7. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
8. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145: 157-162.
9. Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Nephrol 2009; 29: 633-638.
10. Mockenhaupt M, Schopf E. Epidemiology of drug-induced severe skin reactions. Semin Cutan Med Surg 1996; 15: 236-243.
11. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94: 419-436.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
13. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001; 10: 389-392.
14. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, Shaw M, Tilson HH, Joseph M, Dai WS. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991; 10: 565-576.
15. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
16. Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Post-approval drug safety surveillance. Annu Rev Public Health 2010; 31: 419-437.